Evaluation of an alternative ruxolitinib dosing regimen in patients with myelofibrosis: an open-label phase 2 study

被引：0
|
作者：
Moshe Talpaz
Susan Erickson-Viitanen
Kevin Hou
Solomon Hamburg
Maria R. Baer
机构：
[1] University of Michigan,
[2] Incyte Corporation,undefined
[3] Tower Hematology Oncology Medical Group,undefined
[4] University of Maryland,undefined
[5] Greenebaum Comprehensive Cancer Center,undefined
来源：
Journal of Hematology & Oncology | / 11卷
关键词：
Anemia; Janus kinase; Myelofibrosis; Ruxolitinib; Thrombocytopenia; Transfusion;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
相关论文
共 50 条
  • [21] A phase Ib, open-label study of add-on therapy with CK0804 in participants with myelofibrosis and suboptimal response to ruxolitinib
    Masarova, Lucia
    Huang, Meixian
    Goel, Swati
    Bledsoe, Sharon
    Pemmaraju, Naveen
    Kadia, Tapan M.
    Bose, Prithviraj
    Ishizawa, Jo
    Bravo, Guillermo Montalban
    Lyu, Mi-Ae
    Sadeghi, Tara
    Assatiani, Ekaterina
    Parmar, Simrit
    Flowers, Christopher
    Kantarjian, Hagop M.
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [22] The use of erythropoiesis-stimulating agents with ruxolitinib in patients with myelofibrosis in COMFORT-II: An open-label, phase 3 study assessing efficacy and safety of ruxolitinib versus best available therapy in the treatment of myelofibrosis
    McMullin M.F.
    Harrison C.N.
    Niederwieser D.
    Demuynck H.
    Jäkel N.
    Gopalakrishna P.
    McQuitty M.
    Stalbovskaya V.
    Recher C.
    Theunissen K.
    Gisslinger H.
    Kiladjian J.-J.
    Al-Ali H.-K.
    Experimental Hematology & Oncology, 4 (1)
  • [23] Safety and efficacy of jaktinib (a novel JAK inhibitor) in patients with myelofibrosis who are relapsed or refractory to ruxolitinib: A single-arm, open-label, phase 2, multicenter study
    Zhang, Yi
    Zhang, Qike
    Liu, Qingchi
    Dang, Huibing
    Gao, Sujun
    Wang, Wei
    Zhou, Hu
    Chen, Yuqing
    Ma, Liangming
    Wang, Jishi
    Yang, Haiping
    Lu, Binhua
    Yin, Hewen
    Wu, Liqing
    Suo, Shanshan
    Zhao, Qingwei
    Tong, Hongyan
    Jin, Jie
    AMERICAN JOURNAL OF HEMATOLOGY, 2023, 98 (10) : 1579 - 1587
  • [24] Safety and Efficacy of Ruxolitinib in Patients with Myelofibrosis and Low Platelet Counts (50-100 x 109/L): Final Analysis of an Open-Label Phase 2 Study
    Talpaz, Moshe
    Prchal, Josef
    Afrin, Lawrence
    Arcasoy, Murat
    Hamburg, Solomon
    Clark, Jason
    Kornacki, Deanna
    Colucci, Philomena
    Verstovsek, Srdan
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2022, 22 (05): : 336 - 346
  • [25] An open-label study of topical ruxolitinib in necrobiosis lipoidica
    Bhullar, P.
    Boudreaux, B.
    Severson, K.
    Zhang, N.
    Butterfield, R.
    Brumfiel, C.
    Patel, M.
    Li, X.
    Hughes, A.
    Zunich, S.
    Branch, E.
    Nelson, S.
    Sekulic, A.
    Pittelkow, M. R.
    Mangold, A. R.
    JOURNAL OF INVESTIGATIVE DERMATOLOGY, 2022, 142 (08) : B17 - B17
  • [26] A phase 2 study of pracinostat combined with ruxolitinib in patients with myelofibrosis
    Bose, Prithviraj
    Swaminathan, Mahesh
    Pemmaraju, Naveen
    Ferrajoli, Alessandra
    Jabbour, Elias J.
    Daver, Naval G.
    DiNardo, Courtney D.
    Alvarado, Yesid
    Yilmaz, Musa
    Huynh-Lu, Julie
    Qiao, Wei
    Wang, Xuemei
    Matamoros, Aurelio
    Zhou, Lingsha
    Pierce, Sherry
    Schroeder, Kurt D.
    Kantarjian, Hagop M.
    Verstovsek, Srdan
    LEUKEMIA & LYMPHOMA, 2019, 60 (07) : 1767 - 1774
  • [27] A phase 2 study of ruxolitinib in combination with azacitidine in patients with myelofibrosis
    Masarova, Lucia
    Verstovsek, Srdan
    Hidalgo-Lopez, Juliana E.
    Pemmaraju, Naveen
    Bose, Prithviraj
    Estrov, Zeev
    Jabbour, Elias J.
    Ravandi-Kashani, Farhad
    Takahashi, Koichi
    Cortes, Jorge E.
    Ning, Jing
    Ohanian, Maro
    Alvarado, Yesid
    Zhou, Lingsha
    Pierce, Sherry
    Gergis, Romany
    Patel, Keyur P.
    Luthra, Rajyalakshmi
    Kadia, Tapan M.
    DiNardo, Courtney D.
    Borthakur, Gautam
    Bhalla, Kapil
    Garcia-Manero, Guillermo
    Bueso-Ramos, Carlos E.
    Kantarjian, Hagop M.
    Daver, Naval
    BLOOD, 2018, 132 (16) : 1664 - 1674
  • [28] Efficacy and safety of a novel dosing strategy for ruxolitinib in the treatment of patients with myelofibrosis and anemia: the REALISE phase 2 study
    Francisco Cervantes
    David M. Ross
    Atanas Radinoff
    Francesca Palandri
    Alexandr Myasnikov
    Alessandro M. Vannucchi
    Pierre Zachee
    Heinz Gisslinger
    Norio Komatsu
    Lynda Foltz
    Francesco Mannelli
    Francesco Passamonti
    Geralyn Gilotti
    Islam Sadek
    Ranjan Tiwari
    Evren Zor
    Haifa Kathrin Al-Ali
    Leukemia, 2021, 35 : 3455 - 3465
  • [29] Phase III randomized, open-label, active-controlled study of momelotinib versus best available therapy in ruxolitinib-treated patients with myelofibrosis.
    Gupta, Vikas
    Baer, Maria R.
    Oh, Stephen T.
    Miller, Carole Brennan
    Jun, Susie
    Lee, Peter
    Dong, Hua
    Reiter, Andreas
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
  • [30] ASSESSING THE SAFETY AND EFFICACY OF RUXOLITINIB IN AN OPEN-LABEL, MULTICENTER, EXPANDED- ACCESS STUDY IN PATIENTS WITH MYELOFIBROSIS: A 520-PATIENT UPDATE
    Al-Ali, H. K.
    Le Coutre, P.
    Schlag, R.
    Griesshammer, M.
    Tavares, R.
    Martino, B.
    Vannucchi, A. M.
    Castellano, P. G.
    Foltz, L.
    Raanani, P.
    Tannir, B.
    Ghosh, J.
    Ronco, J. P.
    Gupta, V.
    HAEMATOLOGICA, 2014, 99 : 529 - 530
12345